Table 2

Associations with hospitalisation following community acquired COVID-19

ParameterIRD only (n=40)All patients (n=68)
Non-hospitalisationHospitalisationNon-hospitalisationHospitalisation
COVID-19 positive (n, %)34 (85)6 (15)53 (77.9)15 (22.1)
Age in years (mean, SD)48.7 (15)68.9* (15.1)49.6 (13.8)68.1*(12.2)
Female (n, %)26 (76.5)5 (83.3)41 (77.4)10 (66.7)
CVS disease (n, %)2 (5.9%)2 (33.3)6 (11.3%)8*(53.3)
BMI>30 (n, %)8 (23.5)3 (50)13 (24.5)6 (40)
T2DM (n, %)1 (2.9)2† (33.3)1 (1.9)3† (20)
csDMARD (n, %)15 (44.1)5 (83.3)N/A
HCQ (n, %)7 (20.6)2 (33.3)N/A
bDMARD (n, %)16 (47.1)0† (0)N/A
tsDMARD (n, %)0 (0)0 (0)N/A
GC (n, %)0 (0)2† (33.3)0 (0)3* (20)
  • *P≤0.01.

  • †P<0.05.

  • bDMARD, biological disease modifying antirheumatic drug; csDMARD, conventional synthetic disease modifying antirheumatic drug; CVS, cardiovascular disease; GC, glucocorticosteriods; HCQ, hydroxychloroquine; IRD, inflammatory rheumatic disease; T2DM, type 2 diabetes mellitus; tsDMARD, targeted synthetic disease modifying antirheumatic drug.